SK18652000A3 - Farmaceutická kompozícia na báze erytromycínových solí mastných kyselín s 12 až 22 atómami uhlíka vo zvyšku mastnej kyseliny a použitie týchto erytromycínových solí mastných kyselín na topické liečenie kožných ochorení - Google Patents

Farmaceutická kompozícia na báze erytromycínových solí mastných kyselín s 12 až 22 atómami uhlíka vo zvyšku mastnej kyseliny a použitie týchto erytromycínových solí mastných kyselín na topické liečenie kožných ochorení Download PDF

Info

Publication number: SK18652000A3
Authority: SK; Slovakia
Prior art keywords: erythromycin; pharmaceutical composition; fatty acid; skin; acne
Prior art date: 1999-04-19

Application number

SK1865-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Ulrich Knie

Original Assignee

Dr. August Wolff Gmbh & Co. Arzneimittel

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-19

Filing date

2000-04-03

Publication date

2001-08-06

2000-04-03 Application filed by Dr. August Wolff Gmbh & Co. Arzneimittel filed Critical Dr. August Wolff Gmbh & Co. Arzneimittel

2001-08-06 Publication of SK18652000A3 publication Critical patent/SK18652000A3/sk

Links

ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title claims abstract description 91
229960003276 erythromycin Drugs 0.000 title claims abstract description 40
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
230000000699 topical effect Effects 0.000 title claims abstract description 12
208000017520 skin disease Diseases 0.000 title claims abstract description 9
239000002253 acid Substances 0.000 title 1
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 32
239000000194 fatty acid Substances 0.000 claims abstract description 32
229930195729 fatty acid Natural products 0.000 claims abstract description 32
150000004665 fatty acids Chemical class 0.000 claims abstract description 27
208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 22
206010000496 acne Diseases 0.000 claims abstract description 22
-1 erythromycin fatty acid salt Chemical class 0.000 claims abstract description 10
239000007788 liquid Substances 0.000 claims abstract description 9
239000000203 mixture Substances 0.000 claims description 30
239000006071 cream Substances 0.000 claims description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
239000000839 emulsion Substances 0.000 claims description 13
YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical group CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 claims description 6
229960004142 erythromycin stearate Drugs 0.000 claims description 6
239000000499 gel Substances 0.000 claims description 6
239000000725 suspension Substances 0.000 claims description 2
230000035515 penetration Effects 0.000 abstract description 4
125000004432 carbon atom Chemical group C* 0.000 abstract description 3
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 14
239000003755 preservative agent Substances 0.000 description 11
230000002335 preservative effect Effects 0.000 description 10
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 9
238000009472 formulation Methods 0.000 description 9
239000003921 oil Substances 0.000 description 9
239000004480 active ingredient Substances 0.000 description 7
229960000541 cetyl alcohol Drugs 0.000 description 7
XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 7
239000012071 phase Substances 0.000 description 7
235000021355 Stearic acid Nutrition 0.000 description 6
230000001476 alcoholic effect Effects 0.000 description 6
235000011187 glycerol Nutrition 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
239000008117 stearic acid Substances 0.000 description 6
239000008346 aqueous phase Substances 0.000 description 5
239000003925 fat Substances 0.000 description 5
235000004213 low-fat Nutrition 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
210000001732 sebaceous gland Anatomy 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
235000019441 ethanol Nutrition 0.000 description 4
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 3
LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 3
229960002916 adapalene Drugs 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
229940057204 dimethicone 100 Drugs 0.000 description 3
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 3
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 3
238000011835 investigation Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
229960003500 triclosan Drugs 0.000 description 3
241000186427 Cutibacterium acnes Species 0.000 description 2
239000004367 Lipase Substances 0.000 description 2
102000004882 Lipase Human genes 0.000 description 2
108090001060 Lipase Proteins 0.000 description 2
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
239000012458 free base Substances 0.000 description 2
235000021588 free fatty acids Nutrition 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
235000019421 lipase Nutrition 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229940057917 medium chain triglycerides Drugs 0.000 description 2
229960002509 miconazole Drugs 0.000 description 2
BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
229940055019 propionibacterium acne Drugs 0.000 description 2
210000002374 sebum Anatomy 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
AKSNFBZYFYUEGF-UHFFFAOYSA-N (2-aminoacetyl) octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)CN AKSNFBZYFYUEGF-UHFFFAOYSA-N 0.000 description 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 1
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
HDIFHQMREAYYJW-FMIVXFBMSA-N 2,3-dihydroxypropyl (e)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C\CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-FMIVXFBMSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
239000004604 Blowing Agent Substances 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
WHPAGCJNPTUGGD-UHFFFAOYSA-N Croconazole Chemical compound ClC1=CC=CC(COC=2C(=CC=CC=2)C(=C)N2C=NC=C2)=C1 WHPAGCJNPTUGGD-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
241001430197 Mollicutes Species 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
239000004164 Wax ester Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
229960003473 androstanolone Drugs 0.000 description 1
230000003255 anti-acne Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
229960002255 azelaic acid Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
229960003328 benzoyl peroxide Drugs 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
229960004022 clotrimazole Drugs 0.000 description 1
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229960002042 croconazole Drugs 0.000 description 1
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
229960000978 cyproterone acetate Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
229940050781 erythromycin / isotretinoin Drugs 0.000 description 1
229940050580 erythromycin / tretinoin Drugs 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229940075529 glyceryl stearate Drugs 0.000 description 1
ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
229960004068 hexachlorophene Drugs 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229960005280 isotretinoin Drugs 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
230000011268 leukocyte chemotaxis Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000000034 method Methods 0.000 description 1
DWZFNULJNZJRLM-UHFFFAOYSA-N methoxy-dimethyl-trimethylsilylsilane Chemical compound CO[Si](C)(C)[Si](C)(C)C DWZFNULJNZJRLM-UHFFFAOYSA-N 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000003784 poor nutrition Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001107 psychogenic effect Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
238000013112 stability test Methods 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
239000001993 wax Substances 0.000 description 1
235000019386 wax ester Nutrition 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

SK1865-2000A 1999-04-19 2000-04-03 Farmaceutická kompozícia na báze erytromycínových solí mastných kyselín s 12 až 22 atómami uhlíka vo zvyšku mastnej kyseliny a použitie týchto erytromycínových solí mastných kyselín na topické liečenie kožných ochorení SK18652000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19917548A DE19917548A1 (de)	1999-04-19	1999-04-19	Pharmazeutische Zusammensetzung auf der Basis von Erythromycin-Fettsäuresalzen mit 12 bis 22 Kohlenstoffatomen im Fettsäurerest und Verwendung dieser Erythromycin-Fettsäuresalze zur topischen Behandlung von Hauterkrankungen
PCT/EP2000/002950 WO2000062784A1 (de)	1999-04-19	2000-04-03	Pharmazeutische zusammensetzung auf der basis von erythromycin-fettsäuresalzen zur topischen behandlung von hauterkrankungen

Publications (1)

Publication Number	Publication Date
SK18652000A3 true SK18652000A3 (sk)	2001-08-06

Family

ID=7905021

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1865-2000A SK18652000A3 (sk)	1999-04-19	2000-04-03	Farmaceutická kompozícia na báze erytromycínových solí mastných kyselín s 12 až 22 atómami uhlíka vo zvyšku mastnej kyseliny a použitie týchto erytromycínových solí mastných kyselín na topické liečenie kožných ochorení

Country Status (11)

Country	Link
EP (1)	EP1085883A1 (no)
AU (1)	AU4115100A (no)
BG (1)	BG105093A (no)
DE (1)	DE19917548A1 (no)
EE (1)	EE200000727A (no)
HR (1)	HRP20000884A2 (no)
HU (1)	HUP0102702A3 (no)
NO (1)	NO20006260L (no)
PL (1)	PL344988A1 (no)
SK (1)	SK18652000A3 (no)
WO (1)	WO2000062784A1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN114632139B (zh) *	2022-04-02	2023-04-07	北京双吉制药有限公司	一种红霉素药膏及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2383667A1 (fr) *	1977-03-16	1978-10-13	Desjonqueres Stephane	Medicament contre l'acne
US4299826A (en) *	1979-10-12	1981-11-10	The Procter & Gamble Company	Anti-acne composition
IT1210608B (it) *	1980-12-08	1989-09-14	Rorer Int Overseas	Composizione per il trattamento topico dell'acne
DE3375376D1 (en) *	1982-10-15	1988-02-25	Procter & Gamble	Storage stable topical pharmaceutical composition including nitrogen-containing stabilizers
JPS6021831A (ja) *	1983-07-11	1985-02-04	コ−ニング・グラス・ワ−クス	陰極線管のフエ−スプレ−ト用ガラス
LU86945A1 (fr) *	1987-07-17	1989-03-08	Oreal	Compositions pharmaceutiques et cosmetiques a base de pyridones et d'agents antibacteriens
DE19706979A1 (de) *	1997-02-21	1998-08-27	Lindopharm Gmbh	Kombinationspräparat für oral applizierbare Erythromycine

1999
- 1999-04-19 DE DE19917548A patent/DE19917548A1/de not_active Ceased
2000
- 2000-04-03 HU HU0102702A patent/HUP0102702A3/hu unknown
- 2000-04-03 WO PCT/EP2000/002950 patent/WO2000062784A1/de not_active Ceased
- 2000-04-03 EE EEP200000727A patent/EE200000727A/xx unknown
- 2000-04-03 EP EP00920654A patent/EP1085883A1/de not_active Withdrawn
- 2000-04-03 AU AU41151/00A patent/AU4115100A/en not_active Abandoned
- 2000-04-03 PL PL00344988A patent/PL344988A1/xx not_active Application Discontinuation
- 2000-04-03 SK SK1865-2000A patent/SK18652000A3/sk unknown
- 2000-04-03 HR HR20000884A patent/HRP20000884A2/hr not_active Application Discontinuation
- 2000-12-08 NO NO20006260A patent/NO20006260L/no not_active Application Discontinuation
- 2000-12-27 BG BG105093A patent/BG105093A/bg unknown

Also Published As

Publication number	Publication date
NO20006260L (no)	2001-02-19
EP1085883A1 (de)	2001-03-28
HRP20000884A2 (en)	2001-10-31
HUP0102702A3 (en)	2003-02-28
WO2000062784A1 (de)	2000-10-26
AU4115100A (en)	2000-11-02
PL344988A1 (en)	2001-11-19
EE200000727A (et)	2002-04-15
NO20006260D0 (no)	2000-12-08
BG105093A (bg)	2001-07-31
HUP0102702A2 (hu)	2001-12-28
DE19917548A1 (de)	2000-10-26

Publication	Publication Date	Title
JP2023086619A (ja)	2023-06-22	乳化組成物
JP6666068B2 (ja)	2020-03-13	外用組成物
JPS59108716A (ja)	1984-06-23	抗「ざ」瘡組成物
US20190021961A1 (en)	2019-01-24	Water-in-oil emulsion
WO2015075640A1 (en)	2015-05-28	Stable pharmaceutical formulation(s) of tetracycline antibiotic
PL185294B1 (pl)	2003-04-30	Przeciwświądowe kompozycje kosmetyczne i/lub farmaceutyczne, ich zastosowanie do wytwarzania leków i sposób ich wytwarzania
US20050123576A1 (en)	2005-06-09	Mupirocin compositions for topical use, an improved process of making same and methods of using same
AU2004222536A1 (en)	2004-09-30	Skin care product containing tall oil fatty acids and vegetable oils for dry and scaling skin and treatment of psoriasis, dermatitis, and eczemas
EP0183322A2 (en)	1986-06-04	Gel-form topical antibiotic compositions
KR101460777B1 (ko)	2014-11-19	여드름 개선용 화장료 조성물
EP1063969B1 (en)	2002-12-11	Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect
EP2116237A1 (en)	2009-11-11	Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
US20070225234A1 (en)	2007-09-27	Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect
JP2018203674A (ja)	2018-12-27	皮脂分泌促進剤及び外用組成物
CN110944649B (zh)	2024-01-26	鼠李糖及其衍生物作为抗真菌剂的用途
DE60212842T2 (de)	2007-06-28	Dermatologische zusammensetzungen, die nikotinsäure oder nikotinsäureamid und sphingoid-base enthalten
JP3022541B1 (ja)	2000-03-21	外用剤
KR101661694B1 (ko)	2016-10-10	히드로퀴논을 포함하는 저자극성 피부 미백용 조성물
JP7706218B2 (ja)	2025-07-11	皮脂分泌促進剤
JPH07215832A (ja)	1995-08-15	皮膚外用剤
BG105093A (bg)	2001-07-31	Фармацевтичен състав на база на еритромицинови соли на мастни киселини за топично третиране на кожни заболявания
DE102006040450B3 (de)	2008-04-24	Verwendung einer Zusammensetzung für die Hautbehandlung nach Röntgenbestrahlung
JP6853406B1 (ja)	2021-03-31	抗毛嚢炎用外用組成物
CZ20004496A3 (cs)	2001-05-16	Farmaceutická kompozice na bázi erythromycinu ve formě soli mastné kyseliny obsahující ve zbytku mastné kyseliny 12 až 22 uhlíkových atomů a použití erythromycinu ve formě této soli k topickému léčení kožních nemocí
JP7678657B2 (ja)	2025-05-16	皮脂分泌促進剤